U-Systems was acquired by GE Healthcare Limited in November 2012, having developed and commercialized a breakthrough ultrasound system for greater breast cancer detection.
U-Systems was acquired by GE Healthcare Limited in November 2012, having developed and commercialized a breakthrough ultrasound system for greater breast cancer detection.
Spinal Kinetics was acquired by Orthofix in March 2018, having developed advanced artificial discs for degenerative diseases of the spine.
Resonant Medical was acquired by Elekta in May 2010, having developed 3D ultrasound non-invasive and non-ionizing image-guided radiotherapy products for the treatment of cancer.
MAKO Surgical developed a minimally invasive, more confident robotic surgical arm for partial knee and total hip arthroplasty and was acquired by Stryker for $1.65 billion in 2013.
OpSens Medical announced its intent to be aquired by Haemonetics for $345 million in October 2023. The company is a pioneer of innovative fiber optic sensing technology offering more accurate diagnostic and treatment solutions for patients with coronary artery disease.
Histosonics is developing a non-invasive, image-guided method of tumor destruction for more effective cancer treatment, based on the science of histotripsy.
Exact Imaging is the world’s leader in high-resolution systems enabling real-time imaging and guided biopsies for prostate cancer.
Endotronix is developing an integrated platform to provide proactive, comprehensive health management tools for patients suffering from advanced heart failure.
Cardiac Dimensions is developing a minimally invasive implantable product to treat mitral valve regurgitation associated with congestive heart failure.
Cadence Neuroscience is developing a novel neuromodulation therapy with the potential to treat many neurological diseases that cannot be adequately addressed with available treatment options.
Corvia Medical is developing a catheter-delivered implant to reduce symptoms and hospitalizations, while improving the treatment of heart failure with preserved ejection fraction (HFpEF).
Bardy was acquired by Hillrom for $375 million in January 2021, having developed and commercialized the most diagnostically-accurate and patient-friendly cardiac patch and monitoring solutions for patients with cardiovascular disease.